MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./340/0.1/21.03.25 Share Price

Warrant

DE000MG29F00

Market Closed - Börse Stuttgart 17:30:43 04/07/2024 BST
0.28 EUR -3.45% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./340/0.1/21.03.25
Current month-6.67%
1 month+75.00%
Date Price Change
04/07/24 0.28 -3.45%
03/07/24 0.29 -6.45%
02/07/24 0.31 -3.13%
01/07/24 0.32 +6.67%
28/06/24 0.3 +15.38%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 05:30 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG29F0
ISINDE000MG29F00
Date issued 12/04/2024
Strike 340 $
Maturity 21/03/2025 (260 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.32
Lowest since issue 0.1
Spread 0.05
Spread %15.15%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
228.8 USD
Average target price
278.9 USD
Spread / Average Target
+21.86%
Consensus